Transdermal Technology

Transdermal Products

Proprietary Transdermal Technology
Mylan Technologies Inc. (MTI) is the market leader in generic transdermal drug delivery technology. MTI has developed a variety of generic transdermal products available for the U.S. and International markets, and are one of the largest producers of transdermal products in North America. We have built a reputation for delivering exceptional quality through our vertically integrated manufacturing process and modern manufacturing facility.

Advanced TDDS Systems
Currently marketed products include Nitroglycerin, Estradiol and Fentanyl transdermal systems. Our Fentanyl patch was the first generic class II narcotic TDDS ever approved. It is AB-rated alternative to the equivalent branded drug, Duragesic®*.

Nitroglycerin
Our first generic transdermal patch received approval from the FDA on August 30, 1996. This product is prescribed for the prevention of angina pectoris related to coronary artery disease. More than 19 million prescriptions were dispensed in the United States for our product from the year 2000 to 2006.** For additional details including important safety information please see our full prescribing information button below.

Estradiol
Our Estradiol transdermal patch received regulatory approval on February 24, 2000. This product is used to treat certain symptoms of menopause, hypoestrogenism, and for the prevention of post menopausal osteoporosis. Over four million prescriptions were dispensed in the United States for our product from the year 2000 to 2006.** For additional details including important safety information please see our full prescribing information button below.

Fentanyl CII
Our Fentanyl transdermal patch, which received FDA approval on January 28, 2005, provides continuous delivery of fentanyl over 72 hours for the management of persistent, moderate to severe chronic pain. Over three million prescriptions were dispensed in the United States for our product from the year 2005 to 2006.** For additional details including important safety information please see our full prescribing information button below.

EMSAM®***
Somerset Pharmaceuticals, Inc., a joint venture between Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc., received approval from the FDA for EMSAM® transdermal Selegiline, on February 27 of 2006. EMSAM® is the first transdermal treatment for major depressive disorder. All aspects of the EMSAM® product related to its design, chemistry, manufacturing and controls were the result of the integration of the talents and expertise of MTI scientists. EMSAM® is manufactured by MTI. For additional details including important safety information please see our full prescribing information button below.


* Duragesic® is a registered trademark of Johnson & Johnson Corporation
** IMS Data 2000-2006
*** EMSAM® is a registered trademark of Somerset Pharmaceuticals, Inc.